Percheron Therapeutics Limited · ASX:PER
Percheron Therapeutics — Investor Presentation (June 2025)
22 slides from Percheron Therapeutics's investor presentation, Jun 27, 2025
Slide 1: ASX Announcement: Percheron Therapeutics Corporate Presentation
ASX Announcement PERCHERON THERAPEUTICS CORPORATE PRESENTATION Melbourne, Australia – 27 June 2025: Percheron Therapeutics Limited (ASX: PER) (‘the Company’), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to provide an
Slide 2: Developing High Impact Therapies for Cancer and Rare Diseases
For personal use only Developing High Impact Therapies for Cancer and Rare Diseases Corporate Overview June 2025 www.PercheronTx.com ASX: PER | US OTC: PERCF
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions such as the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such
Slide 4: Percheron Therapeutics is a biotech company focused on oncology and rare diseases
Percheron Therapeutics (ASX: PER) is a biotech company focused on oncology and rare diseases • Mid-clinical stage biotech For personal use only • Listed on ASX (PER) and quoted on US OTC Markets (PERCF) • Lead program is HMBD-002, a first-in-class immuno- oncology asset • Potential to target both so
Slide 5: A differentiated investment opportunity in immuno-oncology
Percheron presents a compelling, differentiated investment opportunity in the emerging field of immuno-oncology For personal use only Well-Validated Differentiated, World-Class Clinical and Near-Term Large Commercial Novel Mechanism of Scientifically-Driven Regulatory Package Value-Driving Catalysts
Slide 6: Pipeline with a potential first-in-class immuno-oncology asset
Percheron’s pipeline comprises a potential first-in-class immuno-oncology asset with applicability to a wide range of cancer indications HMBD-002 Monoclonal antibody to VISTA For personal use only TARGET PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Solid Tumours Phase II Trial Initiation Target indicatio
Slide 7: Board and management team with extensive international experience
The Percheron Board and management team bring extensive international experience in drug development, partnering, and commercialisation For personal use only Dr Charmaine Gittleson Dr Gil Price Dr James Garner Deborah Ambrosini Chair of the Board Non-Executive Director CEO & Managing Director Chief
Slide 8: Ultra-lean operating model with majority of cash applied to R&D
AS AT 31 MAR 2025 Percheron benefits from an ultra-lean operating model, with the majority of cash outlays being applied to R&D Operating Cashflows (AU$ ,000) For personal use only 3,000 Corporate Fundamentals (as at 31 March 2025) Market Capitalisation: AU$ 12M 2,000 Primary Listing: ASX: PER 1,000
Slide 9: Value-generating news flow over FY2026
PRELIMINARY Percheron is focused on moving its pipeline forward expeditiously, with potential for rich, value-generating news flow over FY2026 CY2025 For personal use only Publication of HMBD-002 phase I clinical trial results in peer-reviewed journal 2H CY2025 Initiate manufacture of new batch of d
Slide 10: HMBD-002 Monoclonal Antibody to VISTA
For personal use only HMBD-002 Monoclonal Antibody to VISTA Phase II
Slide 11: Immuno-oncology as one of the most important new fields in cancer treatment
Immuno-oncology has emerged in the past decade as one of the most important new fields in the treatment of cancer Immuno-oncology therapies target the interaction between tumours and the Immuno-oncology has grown to a For personal use only immune system to enhance the immunological response to cance
Slide 12: VISTA is a compelling target for novel oncology therapies
VISTA is a compelling target for novel oncology therapies, showing high expression on many tumours and clear correlation with prognosis VISTA is expressed on a wide range of High expression of VISTA is High VISTA expression is associated For personal use only tumours associated with worse prognosis
Slide 13: HMBD-002 is a potent inhibitor of VISTA
HMBD-002 is a potent inhibitor of VISTA, a well-validated immune checkpoint inhibitor Tumours suppress immune function in their local environment; inhibition of For personal use only VISTA reactivates immune function via multiple pathways Reduces myeloid-derived suppressor HMBD-002 is a recombinant
Slide 14: HMBD-002 well-advanced with a clear path to commercialisation
PRELIMINARY HMBD-002 is well-advanced in clinical development, with a clear path to commercialisation Preclinical Development Clinical Development For personal use only ✓ ✓ ✓ Preclinical IND-Enabling NDA-Enabling Phase I Phase II Phase III Validation Toxicology Toxicology Clinical Trial Clinical Tri
Slide 15: Evidence of activity in preclinical tumour models, synergistic with PD-1 inhibition
HMBD-002 has shown compelling evidence of activity in a range of preclinical tumour models, and is synergistic with PD-1 inhibition Monotherapy administration yields up to 80% tumour growth inhibition, Combination with PD-1 inhibition For personal use only depending on tumour type provides substanti
Slide 16: Completed 48-patient phase I study, generally safe and well-tolerated
HMBD-002 has completed a 48-patient phase I study, which has shown the drug to be generally safe and well-tolerated Patient Population & Study Design Dose Escalation For personal use only • Advanced cancer patients with no available Monotherapy Cohort 7 1,400 treatment options known to confer clinic
Slide 17: Common treatment-related adverse events
Common treatment-related adverse events (TRAEs) included infusion reactions, gastrointestinal disorders, fatigue, and rash Few patients with TRAEs at Grade ≥3; For personal use only no incremental toxicity in combination n=28 n=20 100% • Clinical experience comprises 48 patients receiving doses up t
Slide 18: Phase I patients and selected clinical vignettes
The phase I study included late-stage, heavily pre-treated patients with a wide range of tumour types; several patients showed encouraging duration of response Patient Breakdown Selected Clinical Vignettes For personal use only n=28 n=20 100% Pathology Dose Prior History Time on Study Monotherapy 80
Slide 19: Consulting clinicians to determine the optimal path for phase II
ILLUSTRATIVE Percheron will consult clinicians and advisors in 2H CY2025 to determine the optimal path forward for phase II For personal use only Potential Phase II Strategy 1 2 3 Combination with Combination with Monotherapy Existing Other Treatment Potential to deploy more than one Immunotherapies
Slide 20: HMBD-002 arguably the most advanced VISTA antibody in clinical development
INDICATIVE HMBD-002 is arguably the most advanced VISTA antibody in clinical development, and likely the only active member of the IgG4 class Program HMBD-002 CI-8993 JNJ-61610588 SNS-101 W0180 For personal use only Company In general, IgG1 antibodies activate antibody-dependent cellular cytotoxicit
Slide 21: Immuno-oncology assets are highly partnerable, with comparable deals
ILLUSTRATIVE Successful immuno-oncology assets are highly partnerable, with comparable deals suggesting attractive valuations Date Asset Licensor Licensee Target Stage Deal Terms For personal use only Early-Mid Clinical Oct 2018 COM701 PVRIG Phase I / II $20M upfront; $200M milestones; royalties Jun
Slide 22: For personal use only
For personal use only info@PercheronTx.com www.PercheronTx.com 20
Percheron Therapeutics — Investor Presentation (June 2025) on 6ix